Pliant Therapeutics, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed March 16, 2021. This is an annual report, not a standalone fourth-quarter earnings report. Pliant is a clinical-stage biopharmaceutical company focused on fibrosis therapies and had no approved products or product-sales revenue.
Business context and pipeline
The lead wholly owned candidate, PLN-74809, is an oral dual integrin inhibitor in development for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). By year-end, the company had completed Phase 1 studies and was recruiting patients for two Phase 2a IPF trials and one Phase 2a PSC trial. Management expected preliminary data from the first IPF trial in the first half of 2021; it targeted enrollment completion by year-end 2021 for the 12-week IPF trial and mid-2022 for the PSC trial.
PLN-1474, a candidate for NASH-related liver fibrosis, completed Phase 1 and was transferred to Novartis in the first quarter of 2021. Pliant also reported preclinical oncology and muscular dystrophy programs. A separate Phase 2a study of PLN-74809 in COVID-19-related ARDS had begun, but management questioned whether enrollment could be completed as case numbers declined.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue, entirely related-party revenue from Novartis | $41.8 million | $57.1 million |
| Research and development expense | $66.2 million | $47.4 million |
| General and administrative expense | $17.3 million | $10.9 million |
| Operating loss | $41.6 million | $1.2 million |
| Net loss | $41.5 million | $0.6 million |
| Net loss per share, basic and diluted | $1.95 | $4.22 |
| Net cash used in operating activities | $37.3 million | $2.8 million |
Revenue declined 26.7%, primarily because 2019 included recognition of the $50.0 million Novartis upfront license fee. In 2020, Pliant recognized a $25.0 million milestone upon first patient dosing and $16.8 million for research and development services. R&D expense rose 39.8%, reflecting increased clinical-trial activity and external services; G&A expense rose 58.0%, including higher professional fees, staffing and public-company costs. The sharp increase in net loss reflects this higher spending and lower collaboration revenue; per-share comparisons are also affected by the 2020 IPO and preferred-stock conversion.
At December 31, 2020, cash and cash equivalents were $50.9 million and short-term investments were $226.0 million, totaling $276.9 million. Current assets were $290.8 million; total liabilities were $12.5 million. The filing reports no debt balance. Operating lease commitments totaled $9.7 million. Management estimated existing cash, cash equivalents and short-term investments would fund operations into 2023 under its current plan, while also stating that additional capital would be required to complete development programs. No meaningful operating margin is applicable to this loss-making, development-stage business.
Cash flows included $210.9 million used in investing activities, mainly net purchases of short-term investments, and $213.2 million provided by financing activities. Financing included $148.3 million net IPO proceeds, $10.0 million from Novartis’s concurrent private placement and $52.0 million net proceeds from preferred-stock issuance. The IPO and preferred stock conversion materially strengthened the balance sheet.
Outlook, commentary and material risks
- Management expected R&D spending to rise as clinical programs and preclinical work advance. It provided no formal financial revenue or earnings guidance.
- COVID-19 caused clinical-site closures and an estimated four-to-six-month delay to IPF and PSC trial timelines; further enrollment, cost and supply-chain disruption remained possible.
- All reported revenue and accounts receivable in 2020 were attributable to Novartis, creating counterparty and collaboration concentration. The agreement offers up to $416 million in potential milestones plus tiered royalties, but these amounts depend on development, regulatory and commercial achievements and are not assured.
- PLN-74809’s Phase 1 results were described as generally well tolerated, and the Phase 1b study showed dose- and exposure-dependent biomarker effects in healthy volunteers. These findings do not establish clinical benefit in patients; efficacy and safety remain unproven.
- The company depends on third parties for clinical research and manufacturing, including a disclosed sole supplier for PLN-74809, and faces clinical, regulatory, competitive, intellectual-property and financing risks. It expects continuing losses and may need additional capital.
- No material legal proceedings were reported. The auditor issued an unqualified opinion on the financial statements. Management judged disclosure controls effective; the filing did not include management’s assessment or auditor attestation of internal control over financial reporting under the transition relief for newly public companies.
Important facts for investors to verify
- Whether the PLN-74809 trials meet enrollment timelines and produce persuasive patient-level safety, target-engagement and efficacy data.
- Actual cash burn, investment liquidity and whether the stated runway into 2023 remains supportable as trial costs and timelines change.
- Novartis’s continued progress with PLN-1474 and research targets, and the conditions and timing attached to potential milestone and royalty payments.
- Manufacturing continuity, especially the PLN-74809 sole-supplier exposure, and the practical impact of COVID-19 on trials and supply.
- Potential dilution or other financing needs before Pliant can generate product revenue.